200 related articles for article (PubMed ID: 22087267)
1. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients.
Miraglia JL; Abdala E; Hoff PM; Luiz AM; Oliveira DS; Saad CG; Laurindo IM; Viso AT; Tayra A; Pierrotti LC; Azevedo LS; Campos LM; Aikawa NE; Timenetsky Mdo C; Luna E; Cardoso MR; Guedes Jda S; Raw I; Kalil J; Precioso AR
PLoS One; 2011; 6(11):e27214. PubMed ID: 22087267
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.
Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M
Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852
[TBL] [Abstract][Full Text] [Related]
4. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
Van der Vliet D; Pepin S; Lambert M; Fauchoux N; Donazzolo Y; Dupuy M; Dakowski C; Denis M
Hum Vaccin; 2010 Oct; 6(10):823-8. PubMed ID: 20935517
[TBL] [Abstract][Full Text] [Related]
5. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
[TBL] [Abstract][Full Text] [Related]
9. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
10. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.
Busse WW; Peters SP; Fenton MJ; Mitchell H; Bleecker ER; Castro M; Wenzel S; Erzurum SC; Fitzpatrick AM; Teague WG; Jarjour N; Moore WC; Sumino K; Simeone S; Ratanamaneechat S; Penugonda M; Gaston B; Ross TM; Sigelman S; Schiepan JR; Zaccaro DJ; Crevar CJ; Carter DM; Togias A
J Allergy Clin Immunol; 2011 Jan; 127(1):130-7, 137.e1-3. PubMed ID: 21145578
[TBL] [Abstract][Full Text] [Related]
13. HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
Leahy TR; Goode M; Lynam P; Gavin PJ; Butler KM
Influenza Other Respir Viruses; 2014 May; 8(3):360-6. PubMed ID: 24548473
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the immunogenicity of a monovalent influenza A/H1N1 2009 vaccine between healthy individuals, patients with chronic renal failure, and immunocompromised populations.
Watcharananan SP; Thakkinstian A; Srichunrasmee C; Chuntratita W; Sumethkul V
Transplant Proc; 2014; 46(2):328-31. PubMed ID: 24655955
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
Lagler H; Grabmeier-Pfistershammer K; Touzeau-Römer V; Tobudic S; Ramharter M; Wenisch J; Gualdoni GA; Redlberger-Fritz M; Popow-Kraupp T; Rieger A; Burgmann H
PLoS One; 2012; 7(5):e36773. PubMed ID: 22629330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
